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Because the mental retardation caused by some inborn errors of metabolism is to a large degree preventable by appropriate and early therapy, consideration is now being given to the possibility of mass
screening for these disorders in the neonatal period.
Experience with the prototype, the phenylketonuria
(PKU) program, dictates that mass screening for inborn errors of metabolism is here to stay and will
most certainly expand in the future-like it or not.
Since I have recently gained some insight into the field
as Metabolic Consultant to the State Health Department, I wish to review the PKU program in Virginiathe many pitfalls in the diagnosis and treatment of this
disorder, and the feasibility of mass or selective screening for other inborn errors.
Mass Screening
In 1966, Virginia passed a law making it mandatory
to test all newborns for the presence of PKU; indeed,
today most states have such a law. The State Health
Department responded to the legislature's charge to
implement the program by: 1) establishing accurate
Guthrie testing in three State laboratories, 2) establishing a quantitative serum phenylalanine (PA) and
tyrosine procedure at its central laboratory in Richmond, and 3) providing nutritional and medical followup for diagnosed cases. Three full years of experience with the program have demonstrated its worth
not only financially, but also in the prevention of
mental retardation.
From the bookkeeping viewpoint, at $0.42 per test,
97% of the 76,000 births in the State of Virginia last
year were screened for about $31,000. At an incidence
of one in 13,000 it thus costs approximately $6,000 to
uncover one case; it costs another $2,000 to provide
therapy. In contrast, the cost to the State for the
lifetime institutional care of the invariably severely
retarded and untreated PKU patient is, very conservatively, $125,000. One state's estimate put it at twice
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that figure. A recent review of the rolls of the State's
institutions discloses 45 such PKU patients. At present
we are actively treating 30 children at home, most
of them diagnosed since the inception of the testing
program. These compelling statistics should make
believers of any nonbelievers regarding the financial
soundness of the program.
But we must soberly admit what this program hath
wrought, especially in the way of need for a more
precise diagnosis and long term follow-up of positively
screened patients. In the classical phenylketonuric, with
markedly deficient PA hydroxylase activity (Fig 1),
the serum level will reach greater than 20 mg %
by the second week and usually 30-40 mg % by
the third week. 0-hydroxyphenylacetic acid usually appears in the urine when the serum phenylalanine level
reaches 7 mg % , but phenylpyruvic acid is not
excreted in the urine until the serum phenylalanine
reaches 13 to 15 mg % . Because this latter substance
is what makes the ferric chloride test positive, it can
be seen that urine tested under age 2-3 weeks might
be negative despite a high blood level. It is for this
reason that urinary screening gave way to blood
screening via the Guthrie test. Of those who have
a permanent elevation of serum PA (ie, greater than
3-4 mg % ) , approximately % will follow this course
where dietotherapy is necessary to allay mental retardation (Berman et al, 1969).
Because phenylalanine is an essential amino acid it
cannot be completely eliminated from the diet; the
aim therefore is to reach that amount of PA intake
which will maintain the serum level between 3 and 7
mg % (Berry and Wright, 1967). This amounts
to approximately 1A, the normal intake, or 50-80 mg/
kg per day in early infancy and 20-40 mg/kg per day
in older infants and children. Why maintain the serum
level at 3-7 mg when the normal is 1-1.5 mg % ?
If one aims for that normal level too much danger of
undershooting exists, and PA deficiency is almost as
deleterious to the developing infant as hyperphenylalaninemia. In fact, it has caused death in an occasional
infant (Davens et al, 1965). Presently there is a co-.
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operative study underway to determine if the 3-7
mg % range might be relaxed to 10-12 mg %
without deleterious effect, as there is no knowledge
of what level correlates with injury to the developing
central nervous system. These ranges of intake are
only rough guidelines, and frequent monitoring of
serum PA levels by Guthrie testing is required to determine the more exact individual requirements. To
make matters more difficult, these requirements often
change with varying protein needs induced by infection,
changes in the rate of growth, activity, etc.

Variability of Phenylalanine and Protein Needs
Of the 15 cases of phenylketonuria currently
being followed in the MCV Metabolic Endocrine
Clinic, I have selected two which demonstrate these
extremely variable phenylalanine and protein needs.
The first case (Fig 2) is that of a premature baby with
a birth weight of 4 lb at 32 weeks gestation. The
child was referred to MCV at age 3 weeks weighing
3 lb 4 oz, and having a serum PA level of 38 mg
% with a normal serum tyrosine and without
detectable phenylpyruvic acid in the urine. Extreme
lethargy, persistent vomiting, and abdominal distension were present on admission and were not ascribable to other causes (ie, sepsis, organic bowel disease,
etc), and might have been due to the high serum PA
level. For this reason an extremely restricted PA intake of 16 mg/ kg per day was instituted and consequent to the fall in the phenylalanine level, clinical
symptoms disappeared and weight gain ensued. However, with a rapid weight gain the PA needs markedly
increased and even intakes of 80-90 mg/kg per day
did not suffice to maintain the serum PA level above
2 mg % . For this reason it was thought that this
case might merely be one of transient hyperphenylalaninemia and a full phenylalanine intake of 120 mg/
kg per day was offered in the form of regular milk.
This resulted in a rise of serum phenylalanine to 22
mg % . Therefore, an intake of 80-90 mg/ kg was
again used with a consequent fall in the serum PA
again to Jess than 2 mg % . Regular milk supplying 160 mg/kg PA per day raised the level to 15
mg %, and despite a drop in intake to 100-120
mg/ kg per day, it continued to rise to 28 mg % .
This time a decrease in intake to 80-90 mg/ kg brought
the infant to the correct range. By this time the rate of
growth had also slowed somewhat. Since discharge
this child's serum PA level has been maintained between
3-7 mg % on an even more reduced intake of
50 mgjkg per day. This infant, then, with the catch-up
growth typical of the premature, initially required considerably more than the expected amount of dietary
PA (90- 100 mg/ kg per day) .
The second case is that of a 9 year old girl with an
I.Q. of 85 who had findings in early infancy of
classical PKU (Fig 3). She was maintained in fairly
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Fig 1-The classical phenylketonuric with markedly deficient PA hydroxylase activity.
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Fig 2-The course of case one.

,,

.

.

·----· ----------------------------t_-_'! . .... j \\/\/\

r
Jon.
1%7

Joo
1966

Jan.

1%9

.,,
Joo

Fig 3-The course of case two.
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good control through the first five to six years at the
usual intake of 20-30 mg/ kg of PA per day. Thereafter, because almost all brain growth has occurred
by this age and because by intelligence testing and
gross observations there is no deterioration in function when the diet is discontinued, the phenylketonuric
child is usually gradually introduced to a normal PA
intake. However, one very recent careful study suggests a measurable decrease of motor skills and
learning processes may occur with a discontinuation
of the diet at this age (Anderson et al, 1968) . Because of this study, because the mother and child were
most comfortable with the diet, and because the
mother was fearful of any possible deterioration, PA
restriction was continued. However, for the past three
years, despite a low dietary PA intake of 16 mg/kg per
day, the serum PA has been no lower than 12 mg
% . An increase in dietary intake of PA ( as natural
food protein) to 24 mg/kg per day in December, 1969,
merely caused an increase in the serum PA to 22 mg
% . When the protein intake was increased in March,
1970, from a suboptimal level of 0.7 gm/kg per day
to 1.3 gm/ kg per day (by providing additional
Lofenalac) , a lowering of the serum PA to 7 mg %
was effected, despite a small increase in total PA
intake. This child therefore had high serum PA
for several years because tissue protein breakdown
was occurring in the face of inadequate protein
intake. The changing dietary needs demonstrated by
these two cases emphasize the need for constant
monitoring with medical and nutritional supervision
on an individual basis.

Other Causes of Hyperphenylalaninemia
Other than classical PKU there are at least five to
six additional causes of hyperphenylalaninemia. Approximately 2/ 1000 normal newborns have a positive Guthrie test in the screening program, but the
vast majority are due to transient neonatal tyrosinemia. This entity is believed to be due to a delay in the
maturation in the liver of the enzyme parahydroxyphenylpyruvic acid oxidase, and large amounts of
parahydroxyphenylpyruvic acid are usually found in
the urine. Secondarily, serum PA rises and gives the
positive Guthrie test, but serum tyrosine is characteristically much higher than phenylalanine. The values
usually return to normal without therapy in one to
two months, but occasionally not for six to eight
months. No clinically apparent motor or intellectual
deficits result from this transient defect and no treatment is indicated . However, until the tyrosine levels
return to normal it is impossible to be certain that the
enzyme defect is not of a permanent nature, then
called tyrosinosis ( or tyrosinemia). This disorder frequently causes severe liver and kidney damage and
early death. Because it is ameliorated by a low tyrosine diet it becomes imperative that neonatally ele-
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vated tyrosine levels picked up by pos1t1ve Guthrie
tests be followed serially until they become normal.
Another cause of hyperphenylalaninemia of a transient nature is a delay in the maturation of the enzy me PA hydroxylase where the infant initially has
classical findings of PKU but later in infancy tolerates
a normal phenylalanine intake without hyperphenylalaninemia. Because of this possibility the dietary restriction of all infants with what initially appears to
be classical PKU should be relaxed periodically to
demonstrate persistence of the defect, as was done in
my first example.
Of the approximate 1/:i of infants with permanent
hyperphenylalaninemia who do not have the classical
course of PKU, we encounter two generally described
types. One is called atypical PKU, where levels of
greater than 20 mg % are not associated with mental
retardation despite there being no treatment. These
children are usually uncovered as an older sibling of
a newly diagnosed case from the screening program .
The other term, simply hyperphenylalaninemia, is applied when the serum PA level never rises above 20
mg % without dietary restrictions and is usually not
associated with mental retardation. The PA tolerance
tests unfortunately do not distinguish these groups
from the classical PKU patient, but there is some evidence to suggest that the absence in the urine of the
breakdown products of PA, namely phenyl pyruvic acid
and orthohydroxyphenylpyruvic acid, favors a diagnosis of one of these milder forms of the disease. Indeed,
some qualified investigators recommend not treating
an infant unless there are PA metabolites in the urine,
no matter how high the level of serum PA. It is therefore clear that we may be unnecessarily treating, with
inherent dangers, as many as 1/:i of patients thought to
have classical PKU. There is obviously a need for better means of diagnosing these subgroups.
Finally, there is the rare infant who lacks the enzyme phenylalanine transaminase but who only has
hyperphenylalaninemia when on a higher than normal
PA intake. In this instance, of course, no phenyl pyruvic acid or orthohydroxyphenylpyruvic acid appears
in the urine. Space does not permit a more detailed
discussion of these variants, but I have mentioned them
to emphasize that whereas just five years ago hyperphenylalaninemia was thought to be a simple disease
state, mass screening has disclosed a wide spectrum
of clinical and biochemical presentations with variable prognoses and treatment.

Indications for Screening
With some of the machinery already established ,
the next logical question deals with what other inborn
errors should be screened. To answer this it would be
best at this point to review the ten principles of early
detection outlined by a World Health Organization
team a few years ago (Wilson and Junger, 1968) . It
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will be seen that by these criteria the PKU program is a
valid one:
1 ) "The condition should be an important prob-

lem." Although not terribly common, PKU
is important as it is a treatable cause of mental retardation.
2) "There should be an accepted treatment for
patients with recognized disease." There is for
PKU. For other aminoacidopathies it is not
so well worked out-for galactosemia, to be
mentioned shortly, there is an accepted treatment.
3) "Facilities for diagnosis and treatment should
be available." These do exist but are most
marginally funded, so that the more detailed
work-ups required with increasing awareness
of the heterogeneity of the disease are not possible. This will be a drawback to establishing
other mass or selective screening programs.
4) "There should be a recognizable latent or early
symptomatic state." In the instance of PKU
this is hyperphenylalaninemia, but at best
this is likely an early symptomatic stage. Even
dietary therapy instituted at less than 2 months
of age results in only a mean I.Q. of 85 ± 12
vs. the unaffected sibling comparison of I.Q. of

5)
6)
7)

8)

9)

109 ± 11. Whether the treatment is started too
late or is inadequate is not known.
"There should be a suitable test or examination." The Guthrie test fits this bill well.
"The test should be acceptable to the population." The Guthrie test again fits this bill well.
"The natural history of the condition, including
the development from latent to declared disease should be adequately understood." Classical PKU qualifies to a good degree, although
what level of PA or its metabolites is actually
injurious is not yet known-nor is it known
why some patients with significant elevations of
serum PA do not develop retardation, as in
atypical phenylketonuria.
"There should be an agreed policy on whom to
treat as patients." We are in the same trouble
here with PKU because, as mentioned earlier,
some physicians would delay treatment until
metabolic products in the urine appear. Some
use the level of 15 and others 20 mg % before
starting treatment.
"The cost of case finding should be economically
balanced in relation to possible expenditure on
medical care as a whole." As pointed out, PKU
scores high here.

TABLE
Urinary Screening Tests for Metabolic Defects
FeCl,

Disease
I. Phenylketonuria
2. Maple Syrup

3. Tyrosinosis
4. Histidinemia
5. Hyperglycinemia

Green
Navy Blue
Trans. Green
Green

DNPH

C- N

+++
+++
+++
++
+++

7. Galactosemia

++
++

8. Cystinuria
9.
10.
11.
12.
13.
14.
15.

Homocystinuria
Hurler's
Morquio-Ullrich's
Fanconi's
Alkaptonuria
Lowe's
Hyperlysinemia

DNPH
C- N
C-TAB
±

±

±

Brown

C-TAB

±

±(?)

6. Fructose Into!.

Benedict's

±

++
++
++
+

±

+
+

dinitrophenylhydrazine
cyanide nitroprusside
cetyl trimethylammonium bromide
sometimes positive
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10) "Case finding should be a continuing process
and not a once and for all project." This is
certainly true for PKU.
On the basis of these criteria, what other inborn
errors would qualify for mass screening? Most aminoacidopathies probably do not qualify at this time
mainly because of their rarity and of the expensive
chromatographic techniques required, making casefinding too costly. Reduction in cost of detection
might be achieved by the application of the bacterial "inhibition assay" technique as used in the Guthrie test. In this procedure the excessive leucine of
maple syrup urine disease prevents the inhibition of
B. subtilis by 2-methyl leucine, and excessive histidine
of histidinemia prevents inhibition of B. subtilis by
azaserine. With more refined resins and increased
automation, quantification by ion-exchange chromatography might be a useful tool for mass screening of
aminoacidopathies, but this development is several
years away. In the meantime pilot studies in specialized centers are proceeding, using one or two dimensional paper or thin layer chromatography, or
high voltage electrophoresis as screening tools. In
this way more knowledge of these rare diseases and
their treatment can be obtained and we can then
better satisfy criteria 2, 7, and 8, listed above. One
such recent study (Clow, Saiver and Davies, 1969) of
the plasma of over 36,000 neonates revealed 316
with hyperaminoacidemia, but all except six were only
transient. Five of the six permanent elevations were
hyperphenylalaninemias and one was a case of hypermethionemia.
Considerations are somewhat different concerning
the disorder of carbohydrate metabolism, galactosemia. In this disorder a buildup in the blood and tissues
of galactose and galactose-1-phosphate causes mental
retardation, cataracts, liver and kidney disease, and
usually early death. Whereas previous estimates h ave
put the incidence at 1: 50,000, recent mass screening
surveys put it at between 1: 20,000 to 1: 30,000
(Hansen, 1969). Various screening tests are presently
being evaluated-measuring either blood galactose
levels via a bacterial inhibition assay technique or the
actual levels of the deficient enzyme, galactose-1phosphate uridyl transferase, from spotted filter paper
or with 50 microliters of heparinized blood. As for
phenylketonuria and maybe for most inborn errors, it
has already been established that there are several
variants of galactosemia-four at present. It is not
totally clear which types re·q uire therapy, but because
this disease satisfies most of the established principles, with good treatment available (lactose elimination) it would appear that as soon as it is determined
which test is most suitable, it will be the next metabolic disorder to be mass screened. Indeed one state
has already made testing for galactosemia mandatory
34

and several other states are seriously considering it.
There are a host of other inborn metabolic disorders for which diagnostic tests are available, but
their consideration for inclusion in mass screening are
not as pressing as the aforementioned diseases, either
because of their rarity (Wilson's disease), the lack of
adequate therapy, or the lack of a test acceptable to
the population ( cystic fibrosis) .

Selective Screening
Though to this point we have been talking about
mass screening, I would like to discuss one type of
selective screening-that is, the screening of a selected
group. Mental retardates, specifically, are more likely
to have metabolic disorders than the general population. At first blush it would seem to be a waste of time,
effort, and money to seek a diagnosis once mental retardation has already ensued, because in almost all
instances therapy cannot reverse this damage. On the
other hand, several other considerations point out the
validity of testing mental retardates for metabolic disorders.
1) Establishing the cause of retardation enables
better prognosticating and genetic counselling.
2) If therapy is started early with only mild retardation present, further deterioration might
be prevented or slowed.
3) Identifying the inborn error allows a better
determination of its incidence and therefore
its possible worthiness for inclusion in mass
screening programs.
4) Identifying the inborn error may give more
insight into the various modes of clinical
and/ or biochemical presentation and therefore allow earlier recognition of future cases
and determination of appropriate therapy.
There are almost as many screening tests as there
are inborn errors of metabolism, but by selecting a
few tests that will identify several different disorders,
a workable screening panel can be established. The
table depicts such a panel of tests established initially
by R. B. Young (Department of Pediatrics, Medical
College of Virginia) and continued presently by myself
as a service to physicians in the State. In the present
practice, fresh acidified urine of any patient with suspected mental retardation, or with a clinical complex
to suggest an inborn error, is mailed to the Pediatric
Metabolism Laboratory at the Medical College of Virginia. These tests are performed once weekly and the
results mailed promptly to the referring physician.
With more experience with these programs, it is expected that these tests will have to be modified ( as bas
recently been found to be the case for the cyanide
nitroprusside and C-TAB tests) , and others added.
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Summary
I have briefly outlined the PKU program in the
State of Virginia and tried to demonstrate how this
screening experience has disclosed the heterogeneity
of the disease plus the need for an individualized approach to dietary control. I have applied the principles
of mass screening to examine the feasibility of testing
for other inborn errors and, on this basis, feel that
galactosemia will soon next join with PKU. Mass
screening for other aminoacidopathies will await more
refined testing techniques and a definition of their
incidence and mode of therapy. In the meantime,
accumulated experience thus far mandates the establishment of specialized lab facilities and multidisciplinary teams; these will be necessary to effect optimal evaluation and treatment of patients found to be
positive by these screening techniques.
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